Numo vs Biotech Pulse

Just numbers. No distractions. Numo is the simplest way to track your spending. Just open the app, type an amount, and it’s saved automatically with the date and time. That’s it. With a clean, focused interface, Numo helps you keep your spending under control without the need to enter categories, tags, or notes. Perfect for people who just want to know where their money is going—fast. Features: • Add a single expense in seconds • See your total spending for today, this week, and this month • Browse your monthly expense history • Choose a theme that fits your style • No sign-ups, no accounts, no fuss Whether you’re budgeting or just curious about how much you spend, Numo helps you stay aware of your expenses—one number at a time.

The biotech catalyst tracker for serious investors. Real-time FDA approvals, PDUFA dates, EMA and CHMP committee opinions, SEC filings, clinical trial readouts, and primary-source company news — pushed the moment they hit the regulatory record. WHO IT'S FOR Biotech investors, pharma analysts, healthcare hedge funds, and retail traders who need to see what just happened on a name BEFORE the wire-service summary hits Twitter. FREE FEATURES (no account, no signup) • Real-time FDA approval, PDUFA, CRL, and Warning Letter alerts • EU EMA marketing authorisation feed (UK + EEA centralised approvals) • SEC 8-K filings, press releases, and clinical trial updates • Forward catalyst calendar with PDUFA, AdCom, and CHMP dates • Push notifications when a watchlisted ticker has an event • Watchlist + per-ticker News, Pipeline, Drugs, Intelligence tabs • Indication / drug-class search ("multiple sclerosis", "GLP-1", "CAR-T") • Drug detail with FAERS adverse-event severity and primary-source link to Drugs@FDA • Watchlist Compare view — side-by-side pipeline depth + next catalyst BIOTECH PULSE PRO ($9.99/mo or $79.99/yr, with 7-day free trial) Twelve institutional-grade Pro features, every one sourced from a primary regulatory or scientific feed: • Insider buys — SEC Form 4 executive open-market purchases, 10b5-1 plans filtered out • 13F institutional holdings — quarterly changes, biotech-whale callouts (Baker Bros, BVF, RA Capital, Perceptive) • 8-K dilution radar — automatic offering / shelf / ATM classification • 8-K Item 8.01 content classifier — CRL, PDUFA, AdCom, trial readout, partnership, regulatory filing categories • Material agreements — 8-K Item 1.01 partnership / licensing / supply detection • AdCom calendar — Federal Register FDA Advisory Committee meetings + briefing-doc URLs • Orange Book + USPTO patent timelines — every unexpired patent with USPTO Patent Term Adjustment chips (PTA extends patent expiry past the Orange Book listing — the most under-priced biotech signal), Re-exam warning flags, family-size hints, and one-tap to the patent document on Google Patents • FDA Warning Letter history • FDA device clearances — 510(k) and PMA by manufacturer • DailyMed label history — every SPL version bump (indication, black-box, REMS) • CMS Open Payments — KOL payment network per sponsor • CMS Part D utilization — 5 years of Medicare prescription volume • Drug shortages — FDA-tracked active shortages with push alerts on status changes • Conference abstracts — ASH, ASCO, AHA, AAN, DDW • Custom alert rules — unlimited, all 4 trigger types including 8-K Item filtering 100% PRIMARY-SOURCE DATA SEC EDGAR. openFDA. EMA. CHMP. Health Canada. CMS. NIH. Federal Register. ClinicalTrials.gov. DailyMed. USPTO. ash.confex.com. No Bloomberg, no Refinitiv, no FactSet, no paid data vendors. No AI hallucinations. No analyst recommendations. Just the data. NO TRACKING No analytics SDK. No advertising SDK. No cross-app tracking. No account required. External article links open in Safari's isolated process. We don't know who you are. Pro auto-renews unless cancelled at least 24 hours before the end of the current period. Cancel anytime in iOS Settings → Apple ID → Subscriptions. Terms of Use: https://bioturd.com/terms Privacy Policy: https://bioturd.com/privacy